C. Scalbert

537 total citations
6 papers, 170 citations indexed

About

C. Scalbert is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, C. Scalbert has authored 6 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pharmacology, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in C. Scalbert's work include Drug-Induced Adverse Reactions (3 papers), Melanoma and MAPK Pathways (2 papers) and Pharmacovigilance and Adverse Drug Reactions (2 papers). C. Scalbert is often cited by papers focused on Drug-Induced Adverse Reactions (3 papers), Melanoma and MAPK Pathways (2 papers) and Pharmacovigilance and Adverse Drug Reactions (2 papers). C. Scalbert collaborates with scholars based in France, Switzerland and United States. C. Scalbert's co-authors include Laurent Mortier, Jérôme Kluza, P. Guerreschi, Pierre Formstecher, Philippe Marchetti, Stéphane Balayssac, Ariel Savina, Aurélie Jonneaux, Myriam Malet‐Martino and Guillaume Garçon and has published in prestigious journals such as Annals of the Rheumatic Diseases, Oncotarget and Melanoma Research.

In The Last Decade

C. Scalbert

5 papers receiving 168 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Scalbert France	5	115	60	33	19	16	6	170
Kunrui Zhu China	6	139 1.2×	72 1.2×	36 1.1×	26 1.4×	20 1.3×	9	254
Nicolas Cauquil France	5	167 1.5×	34 0.6×	23 0.7×	20 1.1×	9 0.6×	7	201
Lionel Leck Australia	7	108 0.9×	55 0.9×	34 1.0×	8 0.4×	12 0.8×	10	164
Wenke Jin China	9	169 1.5×	33 0.6×	33 1.0×	25 1.3×	9 0.6×	17	256
Jesús García‐Cano Spain	10	179 1.6×	68 1.1×	53 1.6×	21 1.1×	24 1.5×	10	254
Anna‐Lena Scherr Germany	9	153 1.3×	70 1.2×	53 1.6×	16 0.8×	22 1.4×	9	240
Sida Liao China	5	158 1.4×	61 1.0×	27 0.8×	17 0.9×	18 1.1×	6	219
Yiyan Zhai China	9	110 1.0×	42 0.7×	59 1.8×	27 1.4×	8 0.5×	17	197
Lilin Qian China	9	157 1.4×	41 0.7×	70 2.1×	18 0.9×	7 0.4×	17	253
Yaqi Mo China	6	129 1.1×	75 1.3×	70 2.1×	28 1.5×	22 1.4×	9	276

Countries citing papers authored by C. Scalbert

Since Specialization

Citations

This map shows the geographic impact of C. Scalbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Scalbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Scalbert more than expected).

Fields of papers citing papers by C. Scalbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Scalbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Scalbert. The network helps show where C. Scalbert may publish in the future.

Co-authorship network of co-authors of C. Scalbert

This figure shows the co-authorship network connecting the top 25 collaborators of C. Scalbert. A scholar is included among the top collaborators of C. Scalbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Scalbert. C. Scalbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Tison, Alice, Gilles Quéré, L. Misery, et al.. (2018). OP0196 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study. Annals of the Rheumatic Diseases. 77. 147–147. 6 indexed citations

2.

Scalbert, C., et al.. (2018). Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Research. 28(5). 451–457. 13 indexed citations

3.

Yelnik, Cécile, Nadine Petitpain, Hélène Théophile, et al.. (2017). SAT0144 Tumor necrosis factor-alpha inhibitors and psychiatric side effects: results from the french pharmacovigilance database. Annals of the Rheumatic Diseases. 76. 823–824.

4.

Scalbert, C., et al.. (2014). Cabines de bronzage : étude des motivations et croyances des utilisateurs et non-utilisateurs dans la population lilloise. Annales de Dermatologie et de Vénéréologie. 142(1). 10–16. 6 indexed citations

5.

Guerreschi, P., C. Scalbert, Jérôme Kluza, et al.. (2013). Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. Melanoma Research. 23(5). 373–380. 7 indexed citations

6.

Corazao-Rozas, Paola, P. Guerreschi, Manel Jendoubi, et al.. (2013). Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget. 4(11). 1986–1998. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact